Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 13/20 | 0.85 |
| ▸ | MTNR1B | P49286 | 10/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.76 |
| ▸ | MPO | P05164 | 1/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
| ▸ | HTR1A | P08908 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | HPGD | P15428 | 1/20 | 0.76 |
| ▸ | NQO2 | P16083 | 1/20 | 0.76 |
| ▸ | HTR2B | P41595 | 1/20 | 0.76 |
| ▸ | RAB9A | P51151 | 1/20 | 0.76 |
| ▸ | BLM | P54132 | 1/20 | 0.76 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.76 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.76 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31036086 | 0.94 | MTNR1A (0.87) | MTNR1AMTNR1BKMT2AMEN1ALDH1A1 | |
| SCHEMBL1129551 | 0.92 | MTNR1A (0.92) | MTNR1AMTNR1BKMT2AMEN1ALDH1A1 | |
| SCHEMBL8571512 | 0.92 | MTNR1A (0.92) | MTNR1AMTNR1BKMT2AMEN1ALDH1A1 | |
| SCHEMBL7505689 | 0.92 | MTNR1A (0.92) | MTNR1AMTNR1BKMT2AMEN1ALDH1A1 | |
| SCHEMBL5612765 | 0.92 | MTNR1A (0.80) | MTNR1AMTNR1BKMT2AMEN1ALDH1A1 | |
| SCHEMBL16137407 | 0.91 | MTNR1A (0.81) | MTNR1AMTNR1BKMT2AMEN1ALDH1A1 | |
| SCHEMBL17949536 | 0.89 | MTNR1A (0.69) | MTNR1AMTNR1BKMT2AMEN1ALDH1A1 | |
| SCHEMBL29524586 | 0.89 | MTNR1A (0.80) | MTNR1AMTNR1BKMT2AMEN1ALDH1A1 | |
| SCHEMBL19051465 | 0.89 | MTNR1A (0.85) | MTNR1AMTNR1BKMT2AMEN1ALDH1A1 | |
| SCHEMBL14907346 | 0.88 | MTNR1A (0.67) | MTNR1AMTNR1BKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005063240-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF HYPERTENSION | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-07-14 | — | — | WO | claimed |
| US-20050137247-A1 | Methods and compositions for treatment of hypertension | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-06-23 | — | — | US | claimed |
| WO-2024155777-A2 | COMPOSITIONS AND TECHNIQUES FOR TREATMENT OF POLYCYSTIC OVARIAN SYNDROME (PCOS) AND ENDOMETRIOSIS | DARE BIOSCIENCE, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| US-9468670-B2 | Melatonin-based treatment and diagnosis of bile duct disease | TEXAS A&M UNIVERSITY SYSTEM (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160214934-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2016-07-28 | — | — | US | disclosed |
| US-20140079680-A1 | MELATONIN-BASED TREATMENT AND DIAGNOSIS OF BILE DUCT DISEASE | SCOTT & WHITE HEALTHCARE (US) | 2014-03-20 | — | — | US | disclosed |
| WO-2012135848-A2 | MELATONIN-BASED TREATMENT AND DIAGNOSIS OF BILE DUCT DISEASE | SCOTT & WHITE HEALTHCARE (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2007101863-A1 | THERAPEUTIC COMBINATION OF A 5HT2 RECEPTOR ANTAGONIST AND OF A 5HT2 RECEPTOR ACTIVATOR | MACEF (FR) | 2007-09-13 | — | — | WO | disclosed |
| WO-2005063240-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF HYPERTENSION | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| US-20050137247-A1 | Methods and compositions for treatment of hypertension | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2004085395-A1 | MELATONIN DERIVATIVES AND THEIR USE FOR TREATING NEUROLOGICAL DYSFUNCTIONS | FAUST PHARMACEUTICALS (FR) | 2004-10-07 | — | — | WO | disclosed |
| EP-1064284-B1 | HYPNOTIC BETA-CARBOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS | MACEF (FR) | 2002-03-27 | — | — | EP | disclosed |
| US-6048868-A | CIRCADIAN RHYTHM DISORDERS; SLEEP DISORDERS; ANTIDEPRESSANTS | CEMAF (FR) | 2000-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214934-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2, BCL2L1 | MTNR1A 748/4885MTNR1B 1115/4885KMT2A 373/4885 |
| US-20050137247-A1 | Methods and compositions for treatment of hypertension | REN, MTNR1A, MTNR1B | MTNR1A 2/4885MTNR1B 3/4885KMT2A 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.